U.S. Stem Cell, Inc. (USRM)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Feb 9, 2026
U.S. Stem Cell Revenue
In the year 2022, U.S. Stem Cell had annual revenue of $82.05K, down -59.13%. U.S. Stem Cell had revenue of $19.97K in the quarter ending December 31, 2022, a decrease of -15.34%.
Revenue
82.05K
Revenue Growth
-59.13%
P/S Ratio
0.01
Revenue / Employee
7.46K
Employees
11
Market Cap
662.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 82.05K | -118.70K | -59.13% |
| Dec 31, 2021 | 200.75K | -76.34K | -27.55% |
| Dec 31, 2020 | 277.09K | -2.80M | -90.98% |
| Dec 31, 2019 | 3.07M | -3.63M | -54.15% |
| Dec 31, 2018 | 6.70M | 1.18M | 21.38% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nabriva Therapeutics | 29.56M |
| GlobeImmune | 6.21M |
| Alzex Neuropharma | 4.73M |
| DNAPrint Genomics | 1.93M |
| RegeneRx Biopharmaceuticals | 76.76K |
U.S. Stem Cell News
- 4 years ago - Mark Borman Appointed Chairman of the Board of USRM - Accesswire